- AI/ML Innovations (AIML) subsidiary Tech2Heal is launching an independent clinical study to evaluate the effectiveness of Qookka, a depression and anxiety therapy platform
- AI/ML is a business operating in the fields of artificial intelligence and machine learning
- The study is being conducted in partnership with a public hospital and research laboratory in Paris, France
- The goal for this study is to gain “Class IIa” approvals and certification for Qookka as a medical device
- AI/ML Innovations Inc. (AIML) is up 6.45 per cent and is trading at $0.16 per share as of 2:22 p.m. ET
AI/ML Innovations (AIML) subsidiary Tech2Heal is launching an independent clinical study to evaluate the effectiveness of Qookka, a depression and anxiety therapy platform.
AI/ML is a business operating in the growing fields of artificial intelligence and machine learning.
The study is being conducted in partnership with a public hospital and research laboratory in Paris, France.
The company’s goal for this study is to gain “Class IIa” approvals and certification from European health authorities for Qookka as a medical device.
AI/ML described Qookka as a digital therapy solution for anxious and depressed patients. Qookka is based on acceptance and commitment therapy paired with personalized therapy modules for patients and their families and a remote monitoring system for a patient’s progress.
“In addition to Tech2Heal’s plans for Qookka to be recognized as a medical device in Europe, we are also looking forward to the possibility of deploying the technology in the North American marketplace through AI/ML’s majority-owned subsidiary, AI Rx Inc., which owns the distribution rights to this exciting technology in the US and Canada,” said Tim Daniels, Chairman of AI/ML, said.
AI/ML Innovations Inc. (AIML) is up 6.45 per cent and is trading at $0.16 per share as of 2:22 p.m. ET.